Novartis has put some flesh on the bones of its strategy to develop and commercialize more multi-billion dollar blockbuster medicines, especially by improving its performance in the all-important US market.
During a day-long investor meeting at its headquarters in Basel, Switzerland, CEO Vas Narasimhan and a much changed leadership team were quizzed on plans for growth first outlined in April, including how it will maximize the benefits of becoming a ‘pure play’ biopharma company once its generics and biosimilars division Sandoz is spun out
